Amgen developed a humanized monoclonal antibody directed against RANKL (denosumab), which blocks its interaction with RANK, which has become a major therapeutic agent for the treatment of osteoporosis (Prolia) and bone cancer (Xgeva)[3-5]. Here, TNFRSF11A is linked to osteoporosis.